Li and other investigators (136) developed a novel drug, IL-7-Fc fusion protein (NT-I7), which enhances therapeutic efficacy through enhanced proliferation, activation, and prolonged survival of CAR-T cells.NT-I7 was able to significantly boost the number of CD4+ CAR-T cells, reduce the level of depletion markers on T cells, and enhance T cell persistence and tumor penetration. Here, IL7 is linked to neoplasm.